Bristol Myers Q3 2024 revenue $11.9B (+8% YoY); raises full-year guidance, Cobenfy approved

BRISTOL MYERS SQUIBB CO

2024-Q3 EPS reported -$4.45 revenue$35,958,000,000

Q3 2024 revenues $11.9B, up 8% (+10% ex-FX); GAAP EPS $0.60, Non-GAAP EPS $1.80.
Growth Portfolio revenues $5.8B, up 18% (+20% ex-FX).
U.S. approval of Cobenfy (schizophrenia) achieved in Q3.
Raising 2024 revenue guidance to ~+5% (+6% ex-FX); Non-GAAP EPS range raised to $0.75–$0.95.
Net impact of acquired IPRD charges and licensing income reduced EPS by $0.09 on both GAAP and Non-GAAP.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.